MECHANISMS OF ACTION OF ATYPICAL ANTIPSYCHOTIC-DRUGS - IMPLICATIONS FOR NOVEL THERAPEUTIC STRATEGIES FOR SCHIZOPHRENIA

被引:240
作者
DEUTCH, AY
MOGHADDAM, B
INNIS, RB
KRYSTAL, JH
AGHAJANIAN, GK
BUNNEY, BS
CHARNEY, DS
机构
[1] YALE UNIV, SCH MED, DEPT PSYCHIAT, NEW HAVEN, CT 06510 USA
[2] YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA
[3] VET AFFAIRS MED CTR, W HAVEN, CT 06516 USA
关键词
ATYPICAL ANTIPSYCHOTIC DRUG; DOPAMINE; SEROTONIN; CLOZAPINE; RACLOPRIDE; D2 DOPAMINE RECEPTOR; 5-HT2 SEROTONIN RECEPTOR; (SCHIZOPHRENIA);
D O I
10.1016/0920-9964(91)90030-U
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The mechanisms which contribute to the actions of atypical antipsychotic drugs, such as clozapine and the putative atypical agents remoxipride and raclopride, are reviewed. Examination of available preclinical and clinical data leads to two hypotheses concerning the mode of action of atypical antipsychotic drugs. The first hypothesis is that antagonism of the dopamine D2 receptor is both necessary and sufficient for the atypical profile, but that interaction with subtypes of the D2 receptor differentiates typical from atypical antipsychotic drugs. The second hypothesis has been previously advanced, and suggests that a relatively high ratio of serotonin 5-HT2: dopamine D2 receptor antagonism may subserve the atypical profile. It seems likely that the atypical antipsychotic drug profile may be achieved in more than one way.
引用
收藏
页码:121 / 156
页数:36
相关论文
共 342 条
[1]   CLOZAPINE - PHARMACOKINETIC INVESTIGATIONS AND BIOCHEMICAL EFFECTS IN MAN [J].
ACKENHEIL, M .
PSYCHOPHARMACOLOGY, 1989, 99 :S32-S37
[2]  
Aghajanian G K, 1977, Adv Biochem Psychopharmacol, V16, P433
[3]  
AHLFORS UG, 1989, EXCERPTA MED INT C S, V899, P551
[4]   RELATIONSHIPS BETWEEN DRUG CONCENTRATIONS IN SERUM AND CSF, CLINICAL EFFECTS AND MONOAMINERGIC VARIABLES IN SCHIZOPHRENIC-PATIENTS TREATED WITH SULPIRIDE OR CHLORPROMAZINE [J].
ALFREDSSON, G ;
BJERKENSTEDT, L ;
EDMAN, G ;
HARNRYD, C ;
OXENSTIERNA, G ;
SEDVALL, G ;
WIESEL, FA .
ACTA PSYCHIATRICA SCANDINAVICA, 1984, 69 :49-74
[5]   MONOAMINE METABOLITES AND AMINO-ACIDS IN SERUM FROM SCHIZOPHRENIC-PATIENTS BEFORE AND DURING SULPIRIDE TREATMENT [J].
ALFREDSSON, G ;
WIESEL, FA .
PSYCHOPHARMACOLOGY, 1989, 99 (03) :322-327
[6]   EFFECTS OF SULPIRIDE AND CHLORPROMAZINE ON DEPRESSIVE SYMPTOMS IN SCHIZOPHRENIC-PATIENTS - RELATIONSHIP TO DRUG CONCENTRATIONS [J].
ALFREDSSON, G ;
HARNRYD, C ;
WIESEL, FA .
PSYCHOPHARMACOLOGY, 1984, 84 (02) :237-241
[7]  
ALPERT M, 1978, AM J PSYCHIAT, V135, P1329
[8]  
ALTAR CA, 1986, BRAIN RES BULL, V16, P517
[9]  
ALTAR CA, 1988, N-S ARCH PHARMACOL, V338, P162
[10]  
AMLAIKY N, 1986, J NEUROCHEM, V47, P196